AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 17689624
Drug: Conjugated estrogens
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated estrogens (CE), 0.625 mg
Trial: 17689624
Drug: Conjugated estrogens
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated estrogens (CE), 0.45 mg
Trial: 17689624
Drug: Conjugated estrogens
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated estrogens (CE), 0.45 mg and medroxyprogesterone acetate (MPA), 2.5 mg
Trial: 17689624
Drug: Conjugated estrogens
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated estrogens (CE), 0.45 mg and medroxyprogesterone acetate (MPA), 1.5 mg
Trial: 17689624
Drug: Conjugated estrogens
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated estrogens (CE), 0.3 mg
Trial: 15453549
Drug: Ropinirole (0.25-4.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropinirole (0.25-4.0 mg per day)
Trial: 11606148
Drug: Sustained-release sodium
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release sodium fluoride, calcium citrate, and cholecalciferol (SR-NaF group)
Trial: 9613265
Drug: Target-controlled infusion
RxNorm normalized name: Diphtheria toxin-il-3 fusion protein targeting IL-3 receptor
DrugBank: Tagraxofusp (DB14731)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Target-controlled infusion of propofol at 5 micrograms.ml‐1
Trial: 9613265
Drug: Target-controlled infusion
RxNorm normalized name: Diphtheria toxin-il-3 fusion protein targeting IL-3 receptor
DrugBank: Tagraxofusp (DB14731)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Target-controlled infusion of propofol at 6 micrograms.ml‐1
Trial: 9613265
Drug: Target-controlled infusion
RxNorm normalized name: Diphtheria toxin-il-3 fusion protein targeting IL-3 receptor
DrugBank: Tagraxofusp (DB14731)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Target-controlled infusion of propofol at 7 micrograms.ml‐1
Trial: 9613265
Drug: Target-controlled infusion
RxNorm normalized name: Diphtheria toxin-il-3 fusion protein targeting IL-3 receptor
DrugBank: Tagraxofusp (DB14731)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Target-controlled infusion of propofol at 8 micrograms.ml‐1
Trial: 422738
Drug: Loading regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loading regimen of 2600 mg ASA divided into two equal doses 4 hours apart
Trial: 422738
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group received 650 mg ASA every 4 hours for 48 hours
Trial: 31961048
Drug: Branded cream
RxNorm normalized name: Eagle Brand Medicated Oil
DrugBank: Eucalyptus oil (DB11114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Branded cream control
Trial: 22781385
Drug: Pamidronate 90
RxNorm normalized name: pamidronate 90 mg intravenous powder for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pamidronate 90 mg intravenously every 3 to 4 weeks (control)
Trial: 22781385
Drug: Pamidronate 90
RxNorm normalized name: pamidronate 90 mg intravenous powder for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pamidronate 90 mg intravenously every 12 weeks
Trial: 15499601
Drug: Fluorouracil/leucovorin chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluorouracil/leucovorin chemotherapy alone
Trial: 11573600
Drug: Hyaluronidase 150
RxNorm normalized name: hyaluronidase 1500 UNT/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyaluronidase 150 IU ml(‐1)
Trial: 11573600
Drug: 2% lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% lidocaine and 1% ropivacaine with hyaluronidase 150 IU ml(‐1)
Trial: 9745061
Drug: Intermittent sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent sequential compression device
Trial: 10636525
Drug: Intravenous magnesium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous magnesium sulphate
Trial: 31542129
Drug: Very low
RxNorm normalized name: Very low fat spread
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Very low nicotine content cigarettes (0.4 mg nicotine/g tobacco) with transdermal nicotine patch
Trial: 24588277
Drug: Topical ointment
RxNorm normalized name: Topical Ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical ointment (Aquaphor Original Emollient)
Trial: 23164480
Drug: prednisolone 7.5mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: prednisolone 7.5mg once daily
Trial: 23164480
Drug: prednisolone 30mg
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: prednisolone 30mg once daily
Trial: 21107748
Drug: 3.0 g/l
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.0 g/l propofol (n = 64)
Trial: 9438318
Drug: OAC (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OAC (20 mg omeprazole, 750 mg amoxicillin, and 250 mg clarithromycin, twice daily for 10 days)
Trial: 9438318
Drug: BTC (240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BTC (240 mg bismuth subcitrate, 750 mg oxytetracycline, and 250 mg clarithromycin, twice daily for 10 days)
Trial: 8483424
Drug: 3 implants,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 implants, each containing 12 mg oestradiol valerate (E2V)
Trial: 8483424
Drug: 4 implants,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 implants, each containing 27 mg oestradiol benzoate (E2B)
Trial: 3717960
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy of THP, 5-Fluorouracil and cyclophosphamide (Group A)
Trial: 21250568
Drug: Positive control
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Positive control with perlite whitening formulation
Trial: 17943257
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy of TNF inhibitors (etanercept, infliximab, adalimumab) plus methotrexate (MTX)
Trial: 17943257
Drug: TNF-blocking agents
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TNF-blocking agents (etanercept, adalimumab, infliximab)
Trial: 8723581
Drug: Epoetin alfa
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epoetin alfa (100 IU/kg s.c. on days -30, -23, -16, and -9 prior to surgery) with oral iron supplementation
Trial: 1517652
Drug: Oxygen 5
RxNorm normalized name: oxygen 5 %
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen 5 L/min delivered by mask
Trial: 1517652
Drug: Air 5
RxNorm normalized name: Singulair 5mg Chewable Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Air 5 L/min delivered by mask
Trial: 6367246
Drug: 0.20 mg
RxNorm normalized name: FENTANYL 10.20 mg in 1 [USP'U] TRANSDERMAL PATCH [Fentanyl]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.20 mg beta-methyl digoxin
Trial: 25223378
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid 1 mg
Trial: 22906144
Drug: Active acupuncture
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active acupuncture treatment
Trial: 16547082
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose oral amoxicillin (45 mg/kg/day)
Trial: 17430101
Drug: Monoclonal antibody
RxNorm normalized name: Monoclonal antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monoclonal antibody therapies targeting tumor and/or tumor micro-environment in combination with gemcitabine
Trial: 17430101
Drug: Gemcitabine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine plus erlotinib (epidermal growth factor receptor tyrosine kinase inhibitor)
Trial: 18976320
Drug: Antiepileptic drug
RxNorm normalized name: ANTIEPILEPTICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiepileptic drug (AED) monotherapy
Trial: 12796517
Drug: Outpatient conversion
RxNorm normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Outpatient conversion to monotherapy
Trial: 12796517
Drug: Presurgical conversion
RxNorm normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Presurgical conversion to monotherapy
Trial: 10976984
Drug: Prophylactic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic treatment for osteoporosis
Trial: 8879780
Drug: Amphotericin B
RxNorm normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amphotericin B deoxycholate in 5% dextrose (0.7 mg/[kg.d] for 14 days, then 1 mg/kg every other day for 28 days)
Trial: 8879780
Drug: Intralipid/amphotericin B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralipid/amphotericin B (1 mg/[kg.d] for 14 days, then 1.5 mg/kg every other day for 28 days)
Trial: 6866306
Drug: Calcium heparin
RxNorm normalized name: HEPARIN CALCIUM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium heparin prophylaxis (5000 I.U. s.c. every 8 hr)
Trial: 24886027
Drug: Developmentally Adapted
RxNorm normalized name: ADAPT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Developmentally Adapted Cognitive Processing Therapy (D-CPT)
Trial: 21208780
Drug: Brazil nut
RxNorm normalized name: Brazil nut
DrugBank: Brazil nut (DB10510)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brazil nut consumption providing approximately 290 μg of Se a day for 8 weeks
Trial: 21118280
Drug: Dexlansoprazole MR
RxNorm normalized name: Dexlansoprazole
DrugBank: Dexlansoprazole (DB05351)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dexlansoprazole MR 90 mg
Trial: 17645378
Drug: Oral fluconazole
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral fluconazole 300 mg in a single dose per week for 2 weeks
Trial: 17645378
Drug: Oral fluconazole
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral fluconazole 300 mg
Trial: 8355864
Drug: Clonidine 0.125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine 0.125 mg intravenously after induction of anesthesia
Trial: 8355864
Drug: Nitroglycerin infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerin infusion (control)
Trial: 2452254
Drug: Isoprinosine 3
RxNorm normalized name: Isoprénaline
DrugBank: Isoprenaline (DB01064)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isoprinosine 3 g/day
Trial: 18649766
Drug: Alprostadil (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprostadil (20 microg) and radix Salviae miliorrhazae (40 ml) intravenously once a day for 2 weeks
Trial: 18649766
Drug: Enteric coated
RxNorm normalized name: Mesasal Enteric Coated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteric coated aspirin 3 times a day for 2 weeks and radix Salviae miliorrhazae (dropping pill)
Trial: 8958487
Drug: Sufentanil 2
RxNorm normalized name: SUFentanil 250 MCG in 5 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil 2 micrograms mL‐1 + Clonidine 3 micrograms mL‐1 with basal infusion (group SC+)
Trial: 8958487
Drug: Sufentanil 2
RxNorm normalized name: SUFentanil 250 MCG in 5 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil 2 micrograms mL‐1 + Clonidine 3 micrograms mL‐1 without basal infusion (group SC)
Trial: 8958487
Drug: Sufentanil 2
RxNorm normalized name: SUFentanil 250 MCG in 5 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil 2 micrograms mL‐1 with basal infusion (group S+)
Trial: 8958487
Drug: Sufentanil 2
RxNorm normalized name: SUFentanil 250 MCG in 5 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil 2 micrograms mL‐1 without basal infusion (group S)
Trial: 1558400
Drug: UFT treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UFT treatment
Trial: 3847417
Drug: Inpatient cardiac
RxNorm normalized name: Leonurus cardiaca extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inpatient cardiac patient education program consisting of five daily 1-hour classes
Trial: 31945074
Drug: Monthly training
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly training interval
Trial: 26631058
Drug: Omega-3 fatty
RxNorm normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 fatty acids (3.36 g daily for 3 months)
Trial: 12850618
Drug: Nerve stimulation
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nerve stimulation therapy
Trial: 1168110
Drug: Beef lung
RxNorm normalized name: BEEF LUNG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beef lung heparin
Trial: 6344819
Drug: Pork mucosal
RxNorm normalized name: Pork
DrugBank: Pork (DB10561)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pork mucosal heparin
Trial: 6344819
Drug: Both types
RxNorm normalized name: collagen type I
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both types of heparin
Trial: 31062842
Drug: Oral neuromuscular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral neuromuscular training
Trial: 22059736
Drug: Sitagliptin/metformin 50/500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin/metformin 50/500 mg twice daily (up-titrated to 50/1000 mg twice daily)
Trial: 22059736
Drug: Sitagliptin/metformin
RxNorm normalized name: sitagliptin/metformin HCl 50 mg-500 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin/metformin
Trial: 24738695
Drug: Canephron N
RxNorm normalized name: N-6022
DrugBank: N-6022 (DB12206)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canephron N administered with standard antidiabetic therapy and ACE inhibitor
Trial: 24738695
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy and ACE inhibitor alone
Trial: 23744760
Drug: Standard chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard chemotherapy (Arm A)
Trial: 23744760
Drug: Standard chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard chemotherapy with sequential trastuzumab (Arm B)
Trial: 23744760
Drug: Standard chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard chemotherapy with concurrent trastuzumab (Arm C)
Trial: 18378744
Drug: Oral contraceptive
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptive users (77 women)
Trial: 18378744
Drug: Non-oral contraceptive
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-oral contraceptive users (200 women)
Trial: 16181541
Drug: Xueshuantong and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xueshuantong and Betahistine Hydrochloride Injection (BHI), intravenous dripping, once daily for 14 days.
Trial: 12907285
Drug: MCCh formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MCCh formulations
Trial: 24927607
Drug: Filibuvir 600
RxNorm normalized name: Filibuvir
DrugBank: Filibuvir (DB11878)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Filibuvir 600 mg BID plus pegIFN/ribavirin
Trial: 17456679
Drug: Clonidine 0.0
RxNorm normalized name: clonidine 0.09 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine 0.0 mug/mL (C0)
Trial: 17456679
Drug: Clonidine 4.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine 4.0 mug/mL (C4)
Trial: 2667109
Drug: Ciprofloxacin 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 1.5 g/day for seven days
Trial: 2667109
Drug: Doxycycline 100
RxNorm normalized name: doxycycline 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline 100 mg/day for seven days
Trial: 367479
Drug: Electro-convulsive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electro-convulsive therapy (ECT) - six brief pulse unilateral shocks under conventional anaesthesia and muscle relaxation
Trial: 30680611
Drug: Lutein (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lutein (10 mg) and Zeaxanthin (2 mg) supplement
Trial: 26452308
Drug: Child Life
RxNorm normalized name: Senna-Relief Childs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Child Life Therapy (CLT)
Trial: 16714645
Drug: Iodixanol at
RxNorm normalized name: Iodixanol
DrugBank: Iodixanol (DB01249)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iodixanol at a flow rate of 5 mL/sec
Trial: 16714645
Drug: Iodixanol at
RxNorm normalized name: Iodixanol
DrugBank: Iodixanol (DB01249)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iodixanol at a flow rate of 3 mL/sec
Trial: 2880603
Drug: ICI 141,292
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICI 141,292 1 mg
Trial: 2880603
Drug: ICI 141,292
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICI 141,292 4 mg
Trial: 2880603
Drug: ICI 141,292
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICI 141,292 (1, 2, and 4 mg)
Trial: 2880603
Drug: Atenolol 5
RxNorm normalized name: atenolol 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol 5 mg
Trial: 28079793
Drug: Dental treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dental treatments under general anesthesia (GA)
Trial: 28079793
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no GA treatment)
Trial: 28079793
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (before treatment)
Trial: 23841267
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (after treatment)
Trial: 15132723
Drug: GH treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH treatment (0.5, 1.0, and 1.7 IU/m(2) per day)
Trial: 15132723
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose GH treatment
Trial: 3137026
Drug: Flumazenil i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flumazenil i.v. (0.35 +/- 0.15 mg)
Trial: 25604134
Drug: Erlotinib 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib 50 mg
Trial: 25604134
Drug: Erlotinib 100
RxNorm normalized name: erlotinib 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib 100 mg
Trial: 27391356
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment regimen (TPF-E followed by PA-E with XRT)
Trial: 20146063
Drug: Standard-dose EMP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose EMP (560 mg/day)
Trial: 20146063
Drug: PPV plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PPV plus low-dose EMP (280 mg/day)
Trial: 16634855
Drug: Targeted naltrexone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Targeted naltrexone (50 mg/day)
Trial: 16634855
Drug: Daily naltrexone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily naltrexone (50 mg/day)
Trial: 14985695
Drug: Daily placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily placebo
Trial: 19248200
Drug: Omeprazole (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (20 mg once daily for 8 weeks)
Trial: 9882027
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (bismuth subcitrate 120 mg, tetracycline 500 mg, metronidazole 400 mg, all given four times daily) plus omeprazole (20 mg once daily for 8 weeks)
Trial: 8014510
Drug: Oral metronidazole
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral metronidazole (2g)
Trial: 1097035
Drug: L-histidine 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-histidine 4 g/day
Trial: 2499203
Drug: 20 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/kg praziquantel
Trial: 29855373
Drug: 60 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg/kg praziquantel
Trial: 24071051
Drug: Fluoroscopy guided
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoroscopy guided caudal epidural steroid injection (CESI)
Trial: 24071051
Drug: Oral non-steroidal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral non-steroidal anti-inflammatory drugs (NSAIDs)
Trial: 21881324
Drug: Sivelestat sodium
RxNorm normalized name: Sivelestat
DrugBank: Sivelestat (DB12863)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Sivelestat sodium hydrate (0.2 mg/kg/h until weaning from mechanical ventilation)
Trial: 11272721
Drug: HEP A
RxNorm normalized name: Hep A, IG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HEP A vaccine (25 units in 0.5 mL)